Semaglutide 10mg

What Was Semaglutide?

Semaglutide was a major breakthrough in metabolic research, showing safe, effective, and long-lasting results in weight management through its action on GLP-1 (glucagon-like peptide-1) receptors. Clinical studies demonstrated strong evidence of effectiveness, good tolerability, and improvements in multiple aspects of metabolic health.

As a GLP-1 receptor agonist, Semaglutide mimicked a natural hormone that helps regulate appetite, insulin release, and blood sugar levels. In research, it was used to explore how this pathway influences obesity, diabetes, and long-term metabolic balance.

Clinical Trial Results

Semaglutide became widely known after the success of the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trials.

In these studies, participants achieved an average body-weight reduction of around 15% over 68 weeks, and some experienced reductions of up to 17–18%, with some losing more than 20% of their body weight. These results represented some of the strongest outcomes ever seen with a GLP-1–based compound.

Researchers also observed improvements in:

• Insulin sensitivity – how well the body responds to insulin.

• Fasting glucose levels – blood sugar measured after not eating.

• HbA1c – a marker of long-term blood sugar control, showing an improvement of up to 1.5 percentage points.

• Cholesterol and triglycerides – improved lipid profiles.

• Blood pressure and inflammation – indicating better cardiovascular health.

These findings helped establish Semaglutide as a key research compound in metabolic science.

Dosing Used in Clinical Trials

In clinical studies, Semaglutide was administered once weekly by subcutaneous injection — meaning it was injected under the skin, usually in the abdomen, thigh, or upper arm.

Researchers gradually increased the dose over time to help participants’ bodies adjust and to minimise side effects.

The typical dosing schedule used in trials was:

• Started at: 0.25 mg per week for the first 4 weeks

• Then increased to: 0.5 mg per week

• Most participants continued at: 1.0 mg per week

• Some studies tested up to: 2.4 mg per week

These dose levels reflected what was used in controlled clinical research settings to study safety and effectiveness.

How Semaglutide Works

Semaglutide acts on GLP-1 receptors found in the pancreas and the brain.

By mimicking the GLP-1 hormone, it produced several important effects observed in studies:

• Reduced appetite: helped participants feel full sooner and eat less.

• Improved insulin response: supported better control of blood sugar levels.

• Lowered glucagon levels: reduced sugar production by the liver.

• Slowed digestion: helped control portions and reduce calorie intake.

Together, these effects led to consistent fat loss, improved blood-sugar balance, and overall metabolic stability.

Study Highlights

Across major clinical studies:

• Participants lost an average of 10–15% of their body weight, with some losing up to 17–20% at higher doses.

• HbA1c levels improved by up to 1.5 percentage points, reflecting better long-term glucose control.

• Participants reported less hunger and better appetite control.

• Blood pressure and cholesterol improved, supporting cardiovascular health.

These outcomes established Semaglutide as one of the most successful GLP-1–based compounds studied for obesity and metabolic research.

Shipping, Storage, and Reconstitution

Semaglutide vials were securely packaged to ensure stability during shipping.

The dry powder was stored in a cool, dry environment away from light. For long-term storage, it was kept refrigerated or frozen.

Before research use, the powder was mixed with sterile bacteriostatic water to form a solution. After mixing, it was stored in a refrigerator at 2–8 °C and used within standard laboratory timeframes.

For research use only – not for human or veterinary use.